Pattern Of Use Of Belatacept In US Transplant Recipients

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Kidney Transplantation: Transplantation, Kidney

Study type: Observational

Funder types: Industry

Identifiers

NCT01670058

IM103-074

Details and patient eligibility

About

• The prevalence of Belatacept use
• The characteristics of Belatacept users and the temporal trends in these characteristics
• Characteristics of adult kidney-only transplant recipients who are treated with Belatacept vs. who are treated with Calcineurin inhibitors (CNI)-based regimens at the time of transplantation, and the temporal trends in these characteristics during 7 years post approval of Belatacept.

Enrollment: 5,000 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• The cohort for the analyses of all transplants includes all organ transplant recipients who are reported with Belatacept at transplant

Exclusion Criteria:

Trial design

5,000 participants in 2 patient groups

Belatacept treated adult kidney-only transplant recipients

Description:

All adult kidney-only transplant recipients treated with Nulojix (Belatacept)

CNIs at transplantation